Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study (DRACULA 1)

The Role of the Glutamatergic Neurotransmission in Post-partum Depression: an Integrated Molecular-pharmaco-imaging Study

Post-partum depression (PPD) is a prevalent subtype of major depressive disorder that causes a significant distress to the woman and substantial impact on the whole family. Many studies implicate the glutamatergic system in pathological processes relevant to PPD disorders. There is evidence that cell adhesion molecules (CAMs) play a key role in how glutamatergic circuits wire up during development and how glutamatergic synapses, once formed, operate. However, it is unclear how dysregulation in diverse CAMs alter glutamatergic circuitries responsible for emotional and social behavior.

Here, the investigators propose to evaluate the molecular and neurobiological underpinnings of PPD focusing on CAMs at glutamatergic synapses by using an integrated approach from mouse models to human patients. Moreover, the investigators will also perform a pilot study to investigate the impact of selective antidepressants, known to be linked to CAMs, in both human and mice.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Patients will be recruited by the physician in charge of the study or collaborators of the S.C. Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation upon referral from the S.C. Psychiatry of the same institution. In the study, exposure to citalopram treatment will be 12 weeks with follow-up every 4 weeks. At each participant, at the time of enrollment, will be assigned a unique code so that only the local investigators can trace the subject's identity. As part of a scheduled visit to assess the clinical diagnosis, the PPD patient will be offered to participate in the study, after the appropriate signing of informed consent, the verification of absence of criteria for exclusion and existence of the study inclusion criteria. If these criteria are met, some demographic and clinical medical history of the women with PPD will be collected, as already provided by clinical practice for the management of the disease. Patients will undergo MRI scanning at baseline at the S.C. Neuroradiology of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and will begin the pharmacological treatment with citalopram. It is emphasized that the administration of citalopram therapy for the treatment of depressive symptomatology will be proposed and carried out in the patient due to clinical needs, based on the judgment of the competent physician and as would already be the case in practice, thus completely independent of participation or non-participation in the present study. Neuroimaging data will be obtained with a Philips 3T magnetic resonance imaging MRI machine. For each patient enrolled in the study, a structural T1 sequence (3D MPRAGE) is acquired.

T1-weighted MRI images will be used to study the differences brain morphology, including the volumes of gray matter (GM) and white matter (WM) and voxel-based morphometry. In a comparison parallel between regions of interest (ROIs), regional volumes will be estimated using the automated anatomical labeling atlas (AAL) as a reference, with emphasis on the dorsolateral PFC (DL)/ventrolateral (VL), cingulate cortex, amygdala and hippocampus. Further regional analysis will allow estimation, in addition to cortical volumes and subcortical volumes, cortical thickness, cortical surface area, and the cortical gyrification of the Desikan-Killiany atlas regions. During treatment with citalopram, patients will be visited, as per standard clinical practice, every 4 weeks. At each of these follow-up visits will be administered to patients by medical specialists the Brief Psychiatric Rating Scale (BPRS) and the Hamilton Depression Rating Scale (HAM- D) to study symptomatology depression. Patients will be, instead, self-administered in Italian language the Maternal Postnatal Attachment Scale (MPAS) and the Parental Stress Index (PSI) to investigate mother-child attachment and parental stress. The time scheduled for completion of both scales will be about 40 minutes. At 12 weeks, as per practice, the MRI scan will be repeated at the S.C. Neuroradiology Department of the Foundation. The following variables will be collected as part of this study: socio-demographic variables (age, schooling, socio-economic);

  • clinical/anamnestic variables (age of onset, duration of untreated treated, drug therapy, comorbidities, familiarity, substance abuse/dependence);
  • BPRS and HAM-D scales scores for symptomatology assessment (T0, T1, T2, T3);
  • MPAS and PSI scales scores for the assessment of mothers child attachment. (T0, T1, T2, T3);
  • MRI scan data (T0, T3): the images will be used to study brain morphological differences, including GM and WM volumes, and voxel-based morphometry. In a parallel comparison between regions of interest (ROI), regional volumes will be estimated using as a reference the automated anatomical labeling atlas (AAL), with particular attention to the dorsolateral (DL)/ventrolateral (VL) PFC, cingulate cortex, amygdala and hippocampus. A further regional analysis will make it possible to estimate, in addition to cortical and subcortical volumes, the thickness cortical, cortical surface area and cortical gyrification of the Desikan-Killiany atlas regions.

Tipo de estudo

Observacional

Inscrição (Estimado)

15

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Michigan
      • Milan, Michigan, Itália, 20100
        • Recrutamento
        • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 40 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Método de amostragem

Amostra Não Probabilística

População do estudo

Women, aged 18 years to 40 years of age or older, with PPD who will be enrolled by the S.C. Neonatology and Neonatal Intensive Care Unit of the IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation upon referral from the S.C. Psychiatry of the same institution.

Descrição

Inclusion Criteria:

  • Age between 18 and 40 years;
  • female gender;
  • PPD diagnosed by DSM-5 structured clinical interview support (SCID-5) by trained medical personnel;
  • comorbidity with metabolic syndrome, which can lead to brain damage and cognitive flaws;
  • need to start citalopram therapy for clinical needs (and therefore independent of study participation) or already on therapy for no more than two weeks;
  • moderate to severe depression according to the 17-item HAM-D (score 14-24);
  • absence of disabling medical and/or neurological conditions, including heart attacks, brain injuries, neurodegenerative diseases, head trauma with loss of consciousness for more than 30 minutes;
  • Absence of concomitant psychiatric therapies (antidepressants, antipsychotics of the first and second generation and mood stabilizers);
  • absence of contraindications for MRI scanning;
  • patients who have signed informed consent.

Exclusion Criteria:

  • age below 18 years or above 40 years;
  • diagnosis different from PPD based on SCID-5;
  • absence of metabolic syndrome;
  • low depression according to the 17-item HAM-D (score less than 14);
  • presence of disabling medical and/or neurological conditions, including heart attacks, brain injuries, neurodegenerative diseases, head trauma with loss of consciousness for more than 30 minutes;
  • presence of concomitant drug therapies (antidepressants, first- and second-generation antipsychotics and mood stabilizers);
  • presence of contraindications for MRI scanning;
  • presence of contraindications for citalopram;
  • patients who have not signed informed consent.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: CASE_ONLY
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Women with Post-Partum Depression

15 women with PPD referred to the S.C. Psychiatry of IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation and referred to the S.C. Neonatology and Neonatal Intensive Care Unit of the same institution for enrollment.

Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Total White Matter (WM) Volume at Week 12
Prazo: Baseline and week 12

Total white matter volume, expressed in cubic millimeters (mm³), will be estimated from 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner, using tissue segmentation in SPM12 (voxel-based morphometry). A single value per participant (total WM volume) will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.

Baseline and week 12
Change From Baseline in Total Gray Matter (GM) Volume at Week 12
Prazo: Baseline and week 12

Total gray matter volume, expressed in cubic millimeters (mm³), will be estimated from 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner, using tissue segmentation in SPM12 (voxel-based morphometry). A single value per participant (total GM volume) will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.

Baseline and week 12
Change From Baseline in Total Brain Volume at Week 12
Prazo: Baseline and week 12

Total brain volume, expressed in cubic millimeters (mm³), will be calculated as the sum of total gray matter and total white matter volumes obtained from SPM12 segmentation of 3D T1-weighted (MPRAGE) images acquired on a Philips 3T MRI scanner. A single value per participant will be computed at each time point, and the change from baseline (week 12 minus baseline) will be reported.

Baseline and week 12

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Hamilton Depression Rating Scale (HAM-D, 21-item) Total Score at Week 12
Prazo: Baseline and week 12

Depressive symptom severity will be assessed with the clinician-administered 21-item Hamilton Depression Rating Scale (HAM-D). Higher scores indicate more severe depression. The change from baseline (week 12 minus baseline) in total score will be reported.

Baseline and week 12
Percentage of Participants Responding to Treatment at Week 12
Prazo: Baseline and week 12

Response is defined as a reduction of at least 30% in the 21-item Hamilton Depression Rating Scale (HAM-D) total score at week 12 compared with baseline. Higher HAM-D scores indicate more severe depression. The percentage of participants meeting the response criterion will be reported.

Baseline and week 12

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Number of Participants With Adverse Events Related to Citalopram
Prazo: From baseline through week 12

Number of participants experiencing at least one serious or non-serious adverse event judged by the medical staff to be related to citalopram, from treatment start through week 12.

From baseline through week 12

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de agosto de 2023

Conclusão Primária (Estimado)

1 de janeiro de 2027

Conclusão do estudo (Estimado)

1 de julho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

13 de abril de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de novembro de 2023

Primeira postagem (Real)

14 de novembro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever